Body

"

As Chair of the General Studies Unit of the Faculty of Engineering and Computer Science, Dysart-Gale's research normally addresses different research areas. But for a special issue of the Journal of Child and Adolescent Psychiatric Nursing, she produced a review article that's a call to action for nurses to leverage their position in society and clinical milieus.

PHILADELPHIA (October 12, 2010)—In an unexpected twist, Fox Chase Cancer Center researchers find that the loss of a single protein, Nedd9, initially slows cancer formation but then makes the tumors that do arise more aggressive. The good news, though, is that the lack of Nedd9 also makes the aggressive tumors more sensitive to a class of drugs that are already used in the clinic.

WASHINGTON, Oct. 12, 2010 — Key articles in a special print edition of the American Chemical Society journal, Environmental Science & Technology (ES&T), one of the world's premier environmental journals, are now available online. The articles will appear Jan. 1, 2011 in an ES&T issue on environmental policy.

As the population ages, health care epidemiologist Padma Kaul and cardiologist Paul Armstrong, researchers in the Faculty of Medicine & Dentistry at the University of Alberta, want health-care professionals to talk to their patients about their options on places to die, whether it be at home, in hospital or a palliative care facility like hospice.

The researchers found, in their recent study, that the majority of heart failure patients pass away in an acute care hospital and the cost is more than double for those who died elsewhere.

A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).

Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong.

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.

COLUMBIA, Mo. – A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world's most common fatal genetic diseases.

ANN ARBOR, Mich. – University of Michigan scientists have identified events inside insulin-producing pancreatic cells that set the stage for a neonatal form of non-autoimmune type 1 diabetes, and may play a role in type 2 diabetes as well. The results point to a potential target for drugs to protect normally functioning proteins essential for producing insulin.

October 10, 2010─(BRONX, NY) ─Two major international studies looking at data from a quarter of a million people around the globe have found a new set of genes associated with body fat distribution and obesity. Researchers at 280 institutions worldwide, including Albert Einstein College of Medicine of Yeshiva University, conducted the studies.

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.

MANHATTAN, KAN. -- A Kansas State University professor's research and the upcoming Ecological Genomics Symposium continue to make the university a leader in the emerging field of ecological genomics.

Ecological genomics is an integrated field that focuses on how organisms, ecosystems and communities respond to environmental change. It uses genomic technologies, such as gene sequencing and expression analysis, on a wider scale to ask and research ecological questions, said Michael Herman, associate professor of biology.

Scientists have shed light on how malaria is able to resist treatment with a leading drug.

Researchers have identified a gene that enables the parasite that causes the infection to resist treatment with the plant-based remedy artemisinin.

In many countries where the parasite has developed resistance to previously effective common treatments such as chloroquine, artemisinin remains the only effective treatment against the infection. However, malarial resistance to artemisinin appears to be developing, potentially creating problems in controlling malaria.